AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17. Advertisement The oral presentation will provide key results from the TiNivo-2 clinical trial, which … Continue reading Nivolumab Combo Phase 3 TiNivo 2 Results + Tivozanib in RCC Presented at ESMO 2024: AVEO